Patents Assigned to University College Dublin, National University of Ireland, Dublin
-
Patent number: 10557175Abstract: A method for predicting risk of recurrence of cancer in an individual with cancer, the method comprising a step of assaying a cancer sample from the individual for positive expression of at least two genes or proteins encoded by those genes selected from the group consisting of FOXM1, UHRF1, PTTG1, E2F1, MYBL2, HMGB2, ATAD2, E2F8, ZNF367 and TCF19, wherein positive expression of the at least two genes correlates with increased risk of recurrence of cancer compared with an individual who does not exhibit positive expression of the at least two genes or proteins encoded by those genes.Type: GrantFiled: September 18, 2015Date of Patent: February 11, 2020Assignees: THE PROVOST, FELLOWS, SCHOLARS AND OTHER MEMBERS OF BOARD OF TRINITY COLLEGE DUBLIN, UNIVERSITY COLLEGE DUBLIN, NATIONAL UNIVERSITY OF IRELAND, DUBLINInventors: Adrian Bracken, Fiona Lanigan, William Gallagher
-
Patent number: 10436777Abstract: A method for detecting an analyte in a sample, the method comprising contacting the analyte in a sample with nanoparticles comprising a capture probe for capturing said analyte, the capture probe being configured to act as a center for controlled aggregation of nanoparticles with said analyte to form an aggregate of predefined form, detecting the analyte by detecting the shape and/or size of the aggregate is provided. Also provided are nanoparticles comprising a capture probe for capturing an analyte, wherein the capture probe is configured to act as a center for controlled aggregation of nanoparticles with the analyte to form an aggregate of particular detectable size and/or shape, and an assay.Type: GrantFiled: December 5, 2012Date of Patent: October 8, 2019Assignee: University College Dublin, National University of Ireland, DublinInventors: Gil Lee, Mark Platt
-
Patent number: 10386364Abstract: There is provided a method of aggregating a plurality of beads in a magnetic bead aggregation assay for subsequent analysis comprising: —providing magnetic beads comprising a capture probe for binding with said target analyte; —reacting the magnetic beads with the sample including a target analyte in a reaction chamber aggregating the magnetic beads in the presence of a magnetic field with the target analyte to allow formation of magnetic bead aggregates having physical properties detectable to enable characterization of the aggregates on an aggregate by aggregate basis using a detector to measure the physical properties of the aggregates. Further provided are a method and system for detecting analytes in a sample by characterizing the magnetic bead aggregates on an aggregate by aggregate basis by measuring physical properties of the aggregates.Type: GrantFiled: July 9, 2012Date of Patent: August 20, 2019Assignee: University College Dublin, National University of Ireland, DublinInventors: Gil Lee, Peng Li, Mark Platt, Gemma Cannon
-
Publication number: 20190227057Abstract: The invention relates to a sensor molecule for detecting a target molecule comprising: (a) a rod-like molecule L and a rod-like molecule R connected to each other by a joint molecule C to form a hinge; (b) a target binding molecule A bonded to the end of rod-like molecule L opposite to the joint molecule C; (c) a binding molecule A? bonded to the end of rod-like molecule R opposite the joint molecule C; wherein the target binding molecule A is arranged to bind to an epitope or nucleic acid sequence of the target molecule to be detected, and binding molecule A? is arranged to bind to the same epitope or same nucleic acid sequence, or portion thereof of the target molecule as target binding molecule A; and wherein the hinge is biased into an open position, such that target binding molecule A and binding molecule A? are biased apart by the hinge. The invention also relates to analyte dependent activation of pharmaceuticals and chemo-toxins.Type: ApplicationFiled: September 8, 2017Publication date: July 25, 2019Applicant: University College Dublin, National University of Ireland, DublinInventor: Donal Mackernan
-
Patent number: 10357504Abstract: The invention relates to novel chemical entities that act as thromboxane (TX) A2 receptor, or T prostanoid receptor (TP), antagonists and to their use in the treatment of human diseases in which thromboxane (TX) A and of all other agents that act as incidental ligands of TP, including the endoperoxide prostaglandin (PG)G2/PGH2, 20-hydroxyeicosatetraenoic acid (20-HETE) and the free-radical derived isoprostanes (e.g., 8-iso-prostaglandin (PG)F2?), play a role. Compounds of the invention preferably include a benzenesulfonyl urea in which the benzene is substituted by a substituted biphenylyloxy group (e.g., at the 2 position) and by a nitrile group (e.g., at the 5 position), which compounds show promising results as TP-isoform selective TP antagonists.Type: GrantFiled: February 21, 2018Date of Patent: July 23, 2019Assignee: UNIVERSITY COLLEGE DUBLIN, NATIONAL UNIVERSITY OF IRELAND, DUBLINInventors: B. Therese Kinsella, Helen Reid
-
Patent number: 10221427Abstract: The Applicant has identified a novel DON-responsive orphan gene (ENST1—SEQ ID NO: 1), and its promoter, which features DON-responsive elements, which can be used to drive the expression of FHB resistance genes. The Applicant has isolated two variants of the gene from wheat that share approximately 94% homology with ENST1. The Applicant has shown that this gene has homologs of >62% nucleotide sequence identity exist in Aegilops tauschii, Brachypodium distachyon, Festuca pratensis, Hordeum vulgare and Triticum aestivum.Type: GrantFiled: July 15, 2015Date of Patent: March 5, 2019Assignee: University College Dublin, National University of Ireland, DublinInventors: Fiona Doohan, Guillaume Erard, Alexandre Perochon, Khairul Ansari, Arunachalam Chanemougasoundharam, Joanna Kacprzyk
-
Publication number: 20190047853Abstract: A method of generating hydrogen from photoelectrochemical water splitting using a technique that combines an external electric field with light-driven water splitting. In particular, an electric field is applied at a semiconductor-water interface in a manner that boosts the efficiency and performance of photoelectrochemical water splitting, e.g. by selecting properties of the external electric field to increase susceptibility of water molecules to break up. The radiation that drives water-splitting may be solar radiation, which effectively represents a zero-cost energy input. The advantage of the invention arises because the increase in hydrogen generated that follows from application of the external electric field can have a calorific value greater than the energy required to generate the external electric field. The external electric field thus has a quasi-catalytic effect to promote more efficient conversion of the radiation into hydrogen.Type: ApplicationFiled: January 25, 2017Publication date: February 14, 2019Applicant: UNIVERSITY COLLEGE DUBLIN, NATIONAL UNIVERSITY OF IRELAND, DUBLINInventor: Niall J. ENGLISH
-
Patent number: 10022417Abstract: A peptide having 12 to 60 amino acids and including (a) a sequence of SEQUENCE ID NO: 11, or (b) a fragment of SEQUENCE ID NO: 11 that includes the sequence of SEQUENCE ID NO: 1 or 5, is described for use in improving glycemic management in a mammal. A composition, for example a food product, that includes substantially all of the peptides of SEQUENCE ID NO:'s 1 to 11, that is capable of reducing post-prandial blood glucose levels, and increasing insulin secretion in humans, is also described.Type: GrantFiled: May 12, 2015Date of Patent: July 17, 2018Assignees: University College Dublin, National University Of Ireland, Dublin, University of LimerickInventors: Lorraine Brennan, Aisling Robinson, Nessa Noronha, Dick Fitzgerald, Alice Nongonierma, Therese Holton, Helen Roche, J C Jacquier, Denis Shields, Eileen Gibney
-
Patent number: 10005677Abstract: There is provided a method of producing microparticles using an emulsion based synthesis route including: Providing a first fluid phase and a second fluid phase, wherein the first fluid phase is a continuous phase and the second fluid phase is a dispersed phase comprising a dispersed material, wherein the continuous phase is immiscible with the dispersed phase; Mixing the first continuous phase and the second dispersed phase in the presence of a surfactant in a shear device to form an emulsion of droplets of controllable size and having a narrow drop size distribution; Drying the emulsion to form microparticles of controllable size and having narrow size distribution, and wherein the microparticles may comprise spherical, crumpled, dimpled, porous or hollow microparticles morphology. Also provided is a system including shear device and drying arrangement. Also provided are micro particles of controllable size and morphology formed by the method.Type: GrantFiled: May 31, 2013Date of Patent: June 26, 2018Assignee: University College Dublin, National University of Ireland, DublinInventors: Gil Lee, Mark Platt, James O'Mahony
-
Publication number: 20180148788Abstract: A method for predicting risk of recurrence of cancer in an individual with cancer, the method comprising a step of assaying a cancer sample from the individual for positive expression of at least two genes or proteins encoded by those genes selected from the group consisting of FOXM1, UHRF1, PTTG1, E2F1, MYBL2, HMGB2, ATAD2, E2F8, ZNF367 and TCF19, wherein positive expression of the at least two genes correlates with increased risk of recurrence of cancer compared with an individual who does not exhibit positive expression of the at least two genes or proteins encoded by those genes.Type: ApplicationFiled: September 18, 2015Publication date: May 31, 2018Applicants: THE PROVOST, FELLOWS, SCHOLARS AND OTHER MEMBERS OF BOARD OF TRINITY COLLEGE DUBLIN, UNIVERSITY COLLEGE DUBLIN, NATIONAL UNIVERSITY OF IRELAND, DUBLINInventors: Adrian BRACKEN, Fiona LANIGAN, William GALLAGHER
-
Patent number: 9975860Abstract: Compounds and compositions are described which are useful especially for treatment of angiogenesis-related diseases or disorders such as neovascularisation of the eye, age-related macular degeneration, diabetic retinopathy or cancer.Type: GrantFiled: January 15, 2015Date of Patent: May 22, 2018Assignees: University College Dublin, National University of Ireland, Dublin, The Provost Fellows Foundation Scholars and the other members of the Board of the College of the Holy and Undivided Trinity of Queen Elizabeth, near DublinInventors: Breandan Kennedy, Alison Reynolds, Jacintha O'Sullivan, Andrew Douglas Baxter
-
Patent number: 9932304Abstract: The invention relates to novel chemical entities that act as thromboxane (TX) A2 receptor, or T prostanoid receptor (TP), antagonists and to their use in the treatment of human diseases in which thromboxane (TX) A and of all other agents that act as incidental ligands of TP, including the endoperoxide prostaglandin (PG)G2/PGH2, 20-hydroxyeicosatetraenoic acid (20-HETE) and the free-radical derived isoprostanes (e.g., 8-iso-prostaglandin (PG)F2?), play a role. Compounds of the invention preferably include a benzenesulfonyl urea in which the benzene is substituted by a substituted biphenylyloxy group (e.g., at the 2 position) and by a nitrile group (e.g., at the 5 position), which compounds show promising results as TP-isoform selective TP antagonists.Type: GrantFiled: June 13, 2016Date of Patent: April 3, 2018Assignee: UNIVERSITY COLLEGE DUBLIN, NATIONAL UNIVERSITY OF IRELAND, DUBLINInventors: B. Therese Kinsella, Helen Reid
-
Publication number: 20170349952Abstract: A method of determining the risk of metastatic prostate cancer in an individual diagnosed with prostate cancer, the method comprising a step of assaying a biological sample obtained from the individual for the presence of at last one methylated regulatory DNA sequence selected from group comprising: SEQUENCE ID No's 1 to 16, or variants thereof, and correlating the presence or absence of the methylated regulatory DNA sequence with aggressive (metastatic) prostate cancer.Type: ApplicationFiled: December 23, 2015Publication date: December 7, 2017Applicant: UNIVERSITY COLLEGE DUBLIN NATIONAL UNIVERSITY OF IRELAND, DUBLINInventor: Antoinette PERRY
-
Patent number: 9815788Abstract: (E)-2-(2-Quinolin-2-yl-propenyl)-phenol, 2-Quinolin-2-yl-ylethynyl-phenol and salts thereof are useful as medicaments, especially for treatment of an angiogenesis-related disease or disorder.Type: GrantFiled: June 28, 2016Date of Patent: November 14, 2017Assignees: THE PROVOST, FELLOWS, FOUNDATION SCHOLARS, AND THE OTHER MEMBERS OF BOARD, OF THE COLLEGE OF THE HOLY AND UNDIVIDED TRINITY OF QUEEN ELIZABETH NEAR DUBLIN, UNIVERSITY COLLEGE DUBLIN NATIONAL UNIVERSITY OF IRELAND, DUBLINInventors: Breandan Noel Kennedy, Alison Reynolds, Claire Kilty, Jacintha O'Sullivan, Andrew Douglas Baxter
-
Patent number: 9738599Abstract: The invention generally relates to compounds that function as TP antagonists for treating thrombosis and other cardiovascular, renal, or pulmonary diseases. In some embodiments, the invention provides a compound including a substituted nitro phenoxy phenyl, a sulfonylurea, and an alkyl group. In some embodiments, the invention provides a method of treating thrombosis by administering an antithrombotic compound that preferentially binds to a thromboxane receptor, has preferential binding for either TPalpha (TP?) or TPbeta (TP?) receptor subtype.Type: GrantFiled: March 16, 2017Date of Patent: August 22, 2017Assignee: UNIVERSITY COLLEGE DUBLIN, NATIONAL UNIVERSITY OF IRELAND, DUBLINInventors: B. Therese Kinsella, Patrick Guiry, Helen Reid, Barry O'Connor
-
Patent number: 9718781Abstract: The invention generally relates to methods and compounds for treating proliferative disorders, viral infections, or both. In some embodiments, the invention provides an anticancer or antiviral compound including a substituted nitro phenoxy phenyl, a sulfonylurea, and an alkyl group. In some embodiments, the invention provides a method of treating a proliferative disorder or a viral infection including administering an anticancer or antiviral compound that binds to a thromboxane receptor, has preferential binding for either TPalpha (TP?) or TPbeta (TP?) receptor subtype.Type: GrantFiled: April 17, 2013Date of Patent: August 1, 2017Assignee: UNIVERSITY COLLEGE DUBLIN, NATIONAL UNIVERSITY OF IRELAND, DUBLINInventors: B. Therese Kinsella, Helen Reid
-
Patent number: 9675802Abstract: A method and apparatus for stimulating the lower back and abdominal muscles in a patient comprising applying a first electrode A1/A2 substantially centrally to the lower lumbar region of the patient's body, and applying second and third electrodes B, C respectively to opposite side flanks of the patient's body. The electrodes are energized to apply a first group of muscular stimulation current pulses which flow between the second and third electrodes and a second group of muscular stimulation current pulses which flow between the first electrode and the second and third electrodes alternately.Type: GrantFiled: June 16, 2010Date of Patent: June 13, 2017Assignees: University College Dublin, National University of Ireland, Dublin, Bio-Medical Research Ltd.Inventors: Louis Crowe, Brian Caulfield, Conor Minogue
-
Patent number: 9630915Abstract: The invention generally relates to compounds that function as TP antagonists for treating thrombosis and other cardiovascular, renal, or pulmonary diseases. In some embodiments, the invention provides a compound including a substituted nitro phenoxy phenyl, a sulfonylurea, and an alkyl group. In some embodiments, the invention provides a method of treating thrombosis by administering an antithrombotic compound that preferentially binds to a thromboxane receptor, has preferential binding for either TPalpha (TP?) or TPbeta (TP?) receptor subtype.Type: GrantFiled: November 11, 2016Date of Patent: April 25, 2017Assignee: UNIVERSITY COLLEGE DUBLIN, NATIONAL UNIVERSITY OF IRELAND, DUBLINInventors: B. Therese Kinsella, Patrick Guiry, Helen Reid, Barry O'Connor
-
Publication number: 20170050930Abstract: (E)-2-(2-Quinolin-2-yl-propenyl)-phenol, 2-Quinolin-2-yl-ylethynyl-phenol and salts thereof are useful as medicaments, especially for treatment of an angiogenesis-related disease or disorder.Type: ApplicationFiled: June 28, 2016Publication date: February 23, 2017Applicants: University College Dublin National University of Ireland, Dublin, The Provost, Fellows, Foundation Scholars, and the other members of Board, of the College of the HolInventors: Breandan Noel KENNEDY, Alison REYNOLDS, Claire KILTY, Jacintha O'SULLIVAN, Andrew Douglas BAXTER
-
Publication number: 20170010269Abstract: A method is provided for characterising and/or prognosing prostate cancer in a subject comprising measuring the level of at least one protein from a panel or at least one peptide thereof in a sample from the subject. The method may be used to determine the grade and stage of the prostate cancer. Also disclosed is a method for selecting a treatment for prostate cancer, together with corresponding methods of treatment. Systems and computing devices for performing the methods are also provided.Type: ApplicationFiled: December 19, 2014Publication date: January 12, 2017Applicant: University College Dublin, National University of Ireland, DublinInventors: Stephen Pennington, Brendan Murphy, William Watson